Long term efficacy and fate of a right ventricular outflow tract replacement using an elastomeric cardiac patch consisting of caprolactone and D,L-lactide copolymers

2021 ◽  
Vol 123 ◽  
pp. 222-229
Author(s):  
Kazuro L Fujimoto ◽  
Aika Yamawaki-Ogata ◽  
Koichiro Uto ◽  
Akihiko Usui ◽  
Yuji Narita ◽  
...  
2021 ◽  
pp. 1-9
Author(s):  
Adeolu Banjoko ◽  
Golnoush Seyedzenouzi ◽  
James Ashton ◽  
Fatemeh Hedayat ◽  
Natalia N. Smith ◽  
...  

Abstract Surgical repair of Tetralogy of Fallot has excellent outcomes, with over 90% of patients alive at 30 years. The ideal time for surgical repair is between 3 and 11 months of age. However, the symptomatic neonate with Tetralogy of Fallot may require earlier intervention: either a palliative intervention (right ventricular outflow tract stent, ductal stent, balloon pulmonary valvuloplasty, or Blalock-Taussig shunt) followed by a surgical repair later on, or a complete surgical repair in the neonatal period. Indications for palliation include prematurity, complex anatomy, small pulmonary artery size, and comorbidities. Given that outcomes after right ventricular outflow tract stent palliation are particularly promising – there is low mortality and morbidity, and consistently increased oxygen saturations and increased pulmonary artery z-scores – it is now considered the first-line palliative option. Disadvantages of right ventricular outflow tract stenting include increased cardiopulmonary bypass time at later repair and the stent preventing pulmonary valve preservation. However, neonatal surgical repair is associated with increased short-term complications and hospital length of stay compared to staged repair. Both staged repair and primary repair appear to have similar long-term mortality and morbidity, but more evidence is needed assessing long-term outcomes for right ventricular outflow tract stent palliation patients.


2018 ◽  
Vol 9 (5) ◽  
pp. 489-495 ◽  
Author(s):  
Parth M. Patel ◽  
Corinne Tan ◽  
Nayan Srivastava ◽  
Jeremy L. Herrmann ◽  
Mark D. Rodefeld ◽  
...  

Background: Since 1999, we have used the bovine jugular vein conduit for right ventricular outflow tract reconstruction in infants and children. Herein, we review their mid- to long-term outcomes. Methods: Between 1999 and 2016, 315 bovine jugular vein conduits were implanted in 276 patients. Patients were grouped by age at bovine jugular vein conduit implant: group 1: 0 to 1 years (N = 65), group 2: one to ten years (N = 132), and group 3: older than ten years (N = 118). For survival and hemodynamic analysis, additional group stratification was done based on conduit size. Group small: 12 and 14 mm (N = 75), group medium: 16 and 18 mm (N = 84), and group large: 20 and 22 mm (N = 156). Results: Mean follow-up for groups 1, 2, and 3 was 4.0, 4.9, and 5.9 years, respectively. Early mortality was 9%, 0%, and 1% for groups 1, 2, and 3, respectively ( P < .001). Late mortality was 5%, 2%, and 2% for groups 1, 2, and 3, respectively ( P = .337). Group 1 had the lowest ten-year freedom from conduit failure at 13%, versus 53% and 69% for groups 2 and 3, respectively ( P < .001). A total of 21 (6.6%) patients developed endocarditis, 11 (3.5%) patients required reoperation, and 10 (3.2%) patients required antibiotic therapy alone. Conclusions: The bovine jugular vein conduit is a useful option for right ventricular outflow tract reconstruction given its easy implantability and acceptable midterm durability.


EP Europace ◽  
2005 ◽  
Vol 7 (Supplement_1) ◽  
pp. 164-165
Author(s):  
A. Dabrowska-Kugacka ◽  
E. Lewicka-Nowak ◽  
S. Tybura ◽  
R. Wilczek ◽  
J. Staniewicz ◽  
...  

2008 ◽  
Vol 21 (3) ◽  
pp. 195-201 ◽  
Author(s):  
Gabriel Vanerio ◽  
Juan L. Vidal ◽  
Pablo Fernández Banizi ◽  
Daniel Banina Aguerre ◽  
Pablo Viana ◽  
...  

2020 ◽  
Vol 58 (6) ◽  
pp. 1274-1280
Author(s):  
Shuhei Fujita ◽  
Masaaki Yamagishi ◽  
Takako Miyazaki ◽  
Yoshinobu Maeda ◽  
Keiichi Itatani ◽  
...  

Abstract OBJECTIVES In Japan, homograft and bovine jugular vein are available in very limited institutions for the reconstruction of the right ventricular outflow tract, and handmade expanded polytetrafluoroethylene (ePTFE)-valved conduits have been widely used instead. This study aimed to clarify the long-term outcomes and the durability of the ePTFE-valved conduits purely by narrowing down to those with large sizes to eliminate the influence of the body growth. METHODS Between January 2002 and December 2015, patients who underwent right ventricular outflow tract reconstruction in 34 Japanese institutions using ePTFE-valved conduits with a diameter of ≥18 mm were included. All the valved conduits were made in the authors’ institution and delivered to each participating institution. RESULTS Overall, 502 patients were included. Early mortality was 1.4% and not related to conduit failure. The overall survival rate was 98.2% at 5 years and 96.6% at 10 years. Freedom from conduit explantation was 99.5% at 5 years and 89.0% at 10 years. Three patients (0.13 per 100 patient-years) developed infective endocarditis of the conduit, and only 1 patient required conduit removal. Pulmonary insufficiency was mild or less in 480 (96%) patients, and conduit stenosis was mild or less in 436 (88%) patients at the latest follow-up. CONCLUSIONS By narrowing the analyses down to only ePTFE conduits with a large size, satisfactory long-term outcomes of these conduits with a fan-shaped valve and bulging sinuses were shown. These conduits would be among the optimal choices for right ventricular outflow tract reconstruction.


2020 ◽  
Vol 159 (4) ◽  
pp. 1508-1516.e1
Author(s):  
Jamie L.R. Romeo ◽  
Grigorios Papageorgiou ◽  
Johanna J.M. Takkenberg ◽  
Jolien W. Roos-Hesselink ◽  
Wouter J. van Leeuwen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document